---
layout: default
title: Cefuroxime
parent: 僅模型預測 (L5)
nav_order: 66
evidence_level: L5
indication_count: 10
---

# Cefuroxime
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Cefuroxime: From Bacterial Infections to Polyclonal Hyperviscosity Syndrome

## One-Sentence Summary

Cefuroxime is a second-generation cephalosporin antibiotic, widely used in clinical practice to treat bacterial infections of the respiratory tract, urinary tract, skin, and soft tissues.
The TxGNN model predicts it may be effective for **Polyclonal Hyperviscosity Syndrome**, yet **no clinical trials** and **no supporting publications** currently exist for this specific indication.
The mechanistic rationale is indirect at best, making this prediction a speculative network association rather than a grounded repurposing opportunity.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No Philippines registration data available |
| Predicted New Indication | Polyclonal Hyperviscosity Syndrome |
| TxGNN Prediction Score | 99.76% |
| Evidence Level | L5 |
| Philippines Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for cefuroxime in this dataset. Based on established pharmacological knowledge, cefuroxime is a β-lactam antibiotic that exerts bactericidal activity by binding to penicillin-binding proteins (PBPs) on the bacterial cell wall, thereby inhibiting cell wall synthesis and ultimately causing bacterial lysis. It demonstrates stability against many β-lactamases, giving it broader coverage than first-generation cephalosporins against Gram-negative organisms such as *Haemophilus influenzae* and *Klebsiella pneumoniae*.

Polyclonal hyperviscosity syndrome is characterized by elevated serum viscosity due to a pathological rise in polyclonal immunoglobulins, often secondary to chronic infections, autoimmune conditions, or inflammatory states. The only plausible — and very indirect — mechanistic bridge is that if an underlying infection (e.g., Borrelia burgdorferi in Lyme disease) were driving the polyclonal immune response and thus hyperviscosity, cefuroxime's efficacy against such pathogens could theoretically reduce the antigenic stimulus. However, this represents treatment of a causative infection rather than a direct pharmacological action on hyperviscosity itself.

The high TxGNN prediction score almost certainly reflects indirect knowledge-graph network associations (e.g., shared disease nodes or comorbidity pathways) rather than a biologically grounded repurposing signal. Without mechanistic justification or any empirical evidence, this prediction cannot be translated into a clinically actionable hypothesis without substantial further investigation.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Philippines Market Information

Cefuroxime currently has **no registered products** in the Philippines. There are no authorization records on file.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------------------|--------------|-------------|---------------------|
| — | No records available | — | — |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Although the TxGNN model assigned a very high prediction score (99.76%), the absence of any supporting clinical trials or published literature, combined with the lack of a direct mechanistic link between cefuroxime's antibacterial mechanism and polyclonal hyperviscosity syndrome, means this candidate cannot advance beyond the model-prediction stage at this time.

**To proceed, the following is needed:**
- Retrieve and review cefuroxime's full mechanism of action data (e.g., via DrugBank API)
- Conduct a targeted literature review to determine whether any infectious aetiology of polyclonal hyperviscosity is treatable with cefuroxime specifically
- Obtain the Philippines package insert (or equivalent label) to assess key warnings, contraindications, and drug interaction profile
- Perform preclinical or in silico studies to establish whether any direct biological mechanism connects cefuroxime to hyperviscosity pathways
- Evaluate whether a Philippines market registration strategy is feasible if future evidence strengthens the rationale
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

